Thrombokinetics in patients with rheumatoid arthritis treated with D-penicillamine.
AUTOR(ES)
Thomas, D
RESUMO
The mechanism of D-penicillamine induced thrombocytopenia in rheumatoid arthritis was investigated by measuring platelet life-span and platelet production rate in 2 groups of rheumatoid arthritis patients treated with 250-750 mg/day D-penicillamine, 14 with a normal platelet count and 9 with thrombocytopenia (platelet count 50-130 X 10(9)/1). Age matched control patients not treated with D-penicillamine included 14 with rheumatoid arthritis and 9 with osteoarthritis. The platelet life-span was normal, but platelet production rate was significantly reduced in the thrombocytopenic patients, suggesting that D-penicillamine causes thrombocytopenia through bone marrow suppression.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1001358Documentos Relacionados
- Discriminatory indices of response of patients with rheumatoid arthritis treated with D-penicillamine.
- Progressive proliferative glomerulonephritis in a patient with rheumatoid arthritis treated with D-penicillamine.
- Alclofenac and D-penicillamine. Comparative trial in rheumatoid arthritis.
- Myelotoxicity of D-penicillamine.
- D-penicillamine withdrawal in rheumatoid arthritis.
